Literature DB >> 35032666

Cellular and molecular mechanisms implicated in the dual role of ROR2 in cancer.

María Victoria Castro1, Pablo Lopez-Bergami2.   

Abstract

ROR1 and ROR2 are Wnt receptors that are critical for β-catenin-independent Wnt pathways and have been linked to processes driving tumor progression, such as cell proliferation, survival, invasion, and therapy resistance. Both receptors have garnered interest as potential therapeutic targets since they are largely absent in adult tissue, are overexpressed in several cancers, and, as members of the receptor tyrosine kinase family, are easier to target than all other components of the pathway. Unlike ROR1 which always promotes tumorigenesis, ROR2 has a very complex role in cancer acting either to promote or inhibit tumor progression in different tumor types. In the present article, we summarize the findings on ROR2 expression in cancer patients and its impact on clinical outcome. Further, we review the biological processes and signaling pathways regulated by ROR2 that explain its dual role in cancer. Finally, we describe the ongoing strategies to target ROR2 in cancer.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Oncogene; ROR2; Tumor-suppressor gene

Mesh:

Substances:

Year:  2022        PMID: 35032666     DOI: 10.1016/j.critrevonc.2022.103595

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  3 in total

1.  New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome.

Authors:  Juuli Raivola; Alice Dini; Kari Salokas; Hanna Karvonen; Wilhelmiina Niininen; Emilia Piki; Markku Varjosalo; Daniela Ungureanu
Journal:  Cell Mol Life Sci       Date:  2022-05-04       Impact factor: 9.207

2.  ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.

Authors:  María Victoria Castro; Gastón Alexis Barbero; Paula Máscolo; Rocío Ramos; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  Cell Mol Biol Lett       Date:  2022-03-08       Impact factor: 5.787

3.  ROR2, a driver of "phenotype switching" in melanoma?

Authors:  Pablo Lopez-Bergami
Journal:  Cancer Cell Int       Date:  2022-09-20       Impact factor: 6.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.